JP2008523067A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008523067A5 JP2008523067A5 JP2007545547A JP2007545547A JP2008523067A5 JP 2008523067 A5 JP2008523067 A5 JP 2008523067A5 JP 2007545547 A JP2007545547 A JP 2007545547A JP 2007545547 A JP2007545547 A JP 2007545547A JP 2008523067 A5 JP2008523067 A5 JP 2008523067A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- vaccine
- amount
- subject
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940022399 cancer vaccine Drugs 0.000 claims 10
- 238000009566 cancer vaccine Methods 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 108010046075 Thymosin Proteins 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 4
- 230000001939 inductive effect Effects 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 206010046766 uterine cancer Diseases 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 206010068873 Adenosquamous cell carcinoma Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000009956 adenocarcinoma Diseases 0.000 claims 2
- 201000008395 adenosquamous carcinoma Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 229940029030 dendritic cell vaccine Drugs 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000000890 drug combination Substances 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 230000000899 immune system response Effects 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 208000021039 metastatic melanoma Diseases 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- 230000004044 response Effects 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 208000008732 thymoma Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63317504P | 2004-12-06 | 2004-12-06 | |
| PCT/US2005/043985 WO2006062917A2 (en) | 2004-12-06 | 2005-12-06 | Alpha thymosin peptides as cancer vaccine adjuvants |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008523067A JP2008523067A (ja) | 2008-07-03 |
| JP2008523067A5 true JP2008523067A5 (enExample) | 2009-02-19 |
Family
ID=36578462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007545547A Pending JP2008523067A (ja) | 2004-12-06 | 2005-12-06 | 癌ワクチンアジュバントとしてのαサイモシンペプチド |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20100092499A1 (enExample) |
| EP (1) | EP1835931A4 (enExample) |
| JP (1) | JP2008523067A (enExample) |
| KR (1) | KR20070086663A (enExample) |
| CN (1) | CN101072582B (enExample) |
| AU (1) | AU2005314271B2 (enExample) |
| BR (1) | BRPI0518571A2 (enExample) |
| CA (1) | CA2588685A1 (enExample) |
| EA (1) | EA015510B1 (enExample) |
| IL (1) | IL183264A (enExample) |
| MX (1) | MX2007006717A (enExample) |
| NO (1) | NO20072705L (enExample) |
| NZ (1) | NZ555571A (enExample) |
| UA (1) | UA90493C2 (enExample) |
| WO (1) | WO2006062917A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011506467A (ja) * | 2007-12-14 | 2011-03-03 | サイクローン・ファーマシューティカルズ・インコーポレイテッド | 抗悪性腫瘍性熱ショックアポトーシス活性化因子（ｈｓａａ）と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法 |
| EP2427213B1 (en) * | 2009-05-08 | 2015-04-01 | Sciclone Pharmaceuticals, Inc. | Alpha thymosin peptides as vaccine enhancers |
| EP2675272A4 (en) * | 2011-02-09 | 2015-03-11 | Sciclone Pharmaceuticals Inc | THYMOSINE ALPHA PEPTIDE FOR THE PREVENTION, TREATMENT AND TREATMENT OF INFECTIONS |
| BR112014017819B1 (pt) * | 2012-01-20 | 2024-01-09 | Fernando Thomé Kreutz | Método de produzir células cancerígenas imunogênicas isoladas |
| US20150031617A1 (en) * | 2012-03-08 | 2015-01-29 | Sciclone Pharmaceuticals, Inc. | Use of thymosin alpha for treatment of purulent rhinosinusitis |
| EP3943101A1 (en) | 2014-10-21 | 2022-01-26 | SciClone Pharmaceuticals International Ltd. | Treatment of cancer with immune stimulator alpha thymosin peptide |
| CN107281476B (zh) * | 2017-04-06 | 2020-11-24 | 中国医科大学 | 一种抗原肽RL-佐剂CpGODN7909偶联物及其制备方法和应用 |
| RU2645957C1 (ru) * | 2017-04-10 | 2018-02-28 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ лечения лучевых повреждений мочевого пузыря |
| RU2663468C1 (ru) * | 2017-09-25 | 2018-08-06 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ лечения местно-распространенного нерезектабельного рака поджелудочной железы |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US653758A (en) * | 1900-03-20 | 1900-07-17 | Austin Gale | Hay-stacking device. |
| DE2604845A1 (de) | 1976-02-07 | 1977-08-18 | Knoll Ag | Neue piperazinderivate |
| JPH0420624A (ja) * | 1990-02-06 | 1992-01-24 | Kanji Yokoe | 勾配側溝施工法及び当該工法に使用する可変側溝 |
| US6537585B1 (en) * | 1999-03-26 | 2003-03-25 | Guilford Pharmaceuticals, Inc. | Methods and compositions for treating solid tumors |
| JP2004500029A (ja) * | 1999-06-30 | 2004-01-08 | コリクサ コーポレイション | 肺癌の治療および診断のための組成物および方法 |
| JP2005510491A (ja) * | 2001-10-26 | 2005-04-21 | イミュノ−アールエックス， インコーポレイテッド | 免疫抑制を逆転させるための免疫治療 |
| IL161603A0 (en) * | 2001-10-26 | 2004-09-27 | Rhode Island Hospital | Thymosin augmentation of genetic immunization |
| US20060052297A1 (en) | 2002-06-28 | 2006-03-09 | Guido Rasi | Method of up-regulating tumor antigen expression using thymalfasin |
| BRPI0408892A (pt) * | 2003-03-28 | 2006-04-11 | Sciclone Pharmaceuticals Inc | uso de timosina alfa 1 para tratar as infecções por arpergillus |
| ES2428358T3 (es) * | 2003-10-17 | 2013-11-07 | Novo Nordisk A/S | Terapia de combinación |
| EP2427213B1 (en) * | 2009-05-08 | 2015-04-01 | Sciclone Pharmaceuticals, Inc. | Alpha thymosin peptides as vaccine enhancers |
-
2005
- 2005-12-06 CN CN2005800417998A patent/CN101072582B/zh not_active Expired - Lifetime
- 2005-12-06 EA EA200701166A patent/EA015510B1/ru not_active IP Right Cessation
- 2005-12-06 MX MX2007006717A patent/MX2007006717A/es active IP Right Grant
- 2005-12-06 NZ NZ555571A patent/NZ555571A/en not_active IP Right Cessation
- 2005-12-06 US US11/720,909 patent/US20100092499A1/en not_active Abandoned
- 2005-12-06 AU AU2005314271A patent/AU2005314271B2/en not_active Ceased
- 2005-12-06 UA UAA200707406A patent/UA90493C2/ru unknown
- 2005-12-06 JP JP2007545547A patent/JP2008523067A/ja active Pending
- 2005-12-06 EP EP05853022A patent/EP1835931A4/en not_active Withdrawn
- 2005-12-06 WO PCT/US2005/043985 patent/WO2006062917A2/en not_active Ceased
- 2005-12-06 BR BRPI0518571-8A patent/BRPI0518571A2/pt not_active IP Right Cessation
- 2005-12-06 CA CA002588685A patent/CA2588685A1/en not_active Abandoned
- 2005-12-06 KR KR1020077014527A patent/KR20070086663A/ko not_active Ceased
-
2007
- 2007-05-16 IL IL183264A patent/IL183264A/en not_active IP Right Cessation
- 2007-05-29 NO NO20072705A patent/NO20072705L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017171685A5 (enExample) | ||
| Tai et al. | Perioperative influenza vaccination reduces postoperative metastatic disease by reversing surgery-induced dysfunction in natural killer cells | |
| JP2009505676A5 (enExample) | ||
| DE602005026789D1 (de) | Le | |
| JP2006519862A5 (enExample) | ||
| JP2018525358A5 (enExample) | ||
| Shen et al. | HDAC inhibitors enhance the anti-tumor effect of immunotherapies in hepatocellular carcinoma | |
| WO2004071436A3 (en) | The use of gcc ligands | |
| RU2018135317A (ru) | Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии | |
| EA201200560A1 (ru) | Специфическая терапия, использующая интегриновые лиганды для лечения рака | |
| RU2010117635A (ru) | Комбинированная химиотерапия | |
| JP2015512398A5 (enExample) | ||
| JP2006524246A5 (enExample) | ||
| Wang et al. | Role of CD155/TIGIT in digestive cancers: promising cancer target for immunotherapy | |
| RU2017119065A (ru) | Апилимод для применения в лечении рака почек | |
| JP2005533029A5 (ja) | 悪性新生物および他の過剰増殖性疾患の治療におけるラクトフェリン | |
| RU2010122934A (ru) | Фармацевтическая композиция для лечения злокачественных опухолей | |
| WO2006047298A3 (en) | Eph receptor tumor biomarkers | |
| WO2004096159A3 (en) | Saposin c-dops: a novel anti-tumor agent | |
| FI3703747T3 (fi) | NOX4- tai NOX4/1-estäjän käyttö yhdessä immunoterapeuttisen aineen kanssa syövän hoitoon | |
| JP2011503039A5 (enExample) | ||
| JP2020516668A5 (enExample) | ||
| WO2008011710A8 (en) | Cytotoxicity mediation of cells evidencing surface expression of cd63 | |
| EP1667716B8 (en) | Cytotoxicity mediation of cells evidencing surface expression of cd44 | |
| Zhou et al. | A novel tri‐functional liposome Re‐educates “Cold Tumor” and abrogates tumor growth by synergizing autophagy inhibition and PD‐L1 blockade |